For the growing number of patients diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM) — a progressive and historically under-recognized disease where misfolded proteins infiltrate heart tissue — the question of how to optimally sequence or combine emerging therapies has become clinically urgent. A secondary analysis from a major Phase 3 trial now offers a potentially practice-shaping signal.
The CARDIOTTRansform trial tested eplontersen, an antisense oligonucleotide (ASO) that silences transthyretin (TTR) gene expression in the liver, thereby reducing the misfolded protein supply at its source. The secondary analysis, presented at the 2026 ESC Congress and published in Nature Medicine, stratified outcomes by whether patients were already taking TTR stabilizers — drugs like tafamidis that bind to the TTR tetramer to prevent its dissociation and aggregation. The key finding: a beneficial treatment effect from eplontersen was observed only in stabilizer-naive patients, not in those concurrently receiving a stabilizer at baseline.
This finding matters because tafamidis has been the standard of care for ATTR-CM since landmark trial results in 2018, meaning a substantial share of newly diagnosed patients are already stabilizer-treated. The mechanistic logic for the null interaction is plausible: TTR stabilizers preserve tetrameric protein structure, potentially interfering with the cellular turnover and clearance pathways that ASO-mediated knockdown is designed to exploit. If TTR is stabilized, reducing its synthesis may offer diminishing marginal benefit.
This is a secondary analysis, which limits causal inference — subgroup interactions must be interpreted cautiously, and the stabilizer-naive group may differ systematically from stabilizer-users in disease stage or genetics. Nevertheless, originating from a well-powered Phase 3 RCT in a high-impact journal, the finding is credible enough to reshape prescribing logic and warrants prospective confirmation. It suggests that the sequence of therapy — not just the choice — may determine outcomes in ATTR-CM.